Hye Min Kim

Hye Min Kim

Auto-generated profile, based on publicly available information

Hye Min Kim

Biopharmaceutical Research Center, Korea Basic Science Institute (KBSI), Cheongju, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JMJin Young Min
Jin Young Min
HKHye Min Kim
Hye Min Kim
HLHyunseung Lee
Hyunseung Lee
MCMi Young Cho
Mi Young Cho
HPHye Sun Park
Hye Sun Park
EHEunhee Han
Eunhee Han
Natural killer (NK) cells play a crucial role in immunotherapy for cancer due to their natural ability to target and destroy cancer cells. However, current methods to visualize NK cells’ activity against tumors in live organisms are limited. We introduce an imaging method that non-invasively tracks NK cell activation by cancer cells through the STAT1 protein. To achieve this, we modified NK cells to include a specific genetic sequence that binds to STAT1 when activated. These engineered NK cells (GAS-NK) demonstrate their functionality through various biological tests and analysis. Observations of changes in cancer environments and patient-derived cancer organoid models further confirm the effectiveness of this approach. Our method provides a way to monitor NK cell activity, which could improve the prediction and effectiveness of NK cell-based cancer therapies, contributing to advances in cancer treatment.

28 September 2026 in Pharmacological Research
Verified
Journal Article
Open access
JMJin Young Min
Jin Young Min
MGMin Ji Gu
Min Ji Gu
HKHye Min Kim
Hye Min Kim
DKDonghwan Kim
Donghwan Kim
GBGeul Bang
Geul Bang
EHEun Hee Han
Eun Hee Han

20 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JMJin Young Min
Jin Young Min
MGMin Ji Gu
Min Ji Gu
HKHye Min Kim
Hye Min Kim
DKDonghwan Kim
Donghwan Kim
GBGeul Bang
Geul Bang
EHEun Hee Han
Eun Hee Han
Steatotic liver disease is associated with advanced glycation end-product (AGE) accumulation, but the pathogenic AGE species and mechanisms remain unclear. We investigated whether Nε-(carboxymethyl)lysine (CML) induces hepatic fibrogenic responses and whether CML-associated programs in human liver organoids (HLOs) are reflected in patient biospecimens. AGE–RAGE pathway activity was assessed in three public liver transcriptomic cohorts, and CML and total AGEs were quantified in liver and serum. Models included C57BL/6J mice, HepG2 2D/3D systems, and multicellular HLOs; translational concordance was assessed by serum cytokine and liver proteomic profiling. AGE–RAGE pathway activity was elevated in NASH-related diagnostic and histological categories, and hepatic CML—but not total AGE or serum CML—was increased in steatosis. Oral CML activated AGE–RAGE- and tumor growth factor-β-related programs but caused minimal fibrosis; HepG2 models failed to reproduce CML-driven lipid accumulation. In HLOs, CML induced lipid accumulation and fibrogenic remodeling through a program distinct from oleic acid-driven lipotoxicity. Single-cell RNA sequencing revealed shifts in hepatocyte-, Kupffer-, and stellate-like populations, mitochondrial dysfunction in hepatocyte-like cells, and collagen assembly pathway activation. Functional assays confirmed oxidative stress, NF-κB-dependent cytokine release, stellate cell activation, and collagen deposition; selected responses were attenuated by N-acetylcysteine, clodronate, 2-deoxyglucose, or NF-κB inhibition. Steatosis biospecimens showed partial concordance with CML–HLO-associated inflammatory and fibrogenic programs. Collectively, CML preferentially accumulates in steatotic liver tissue and promotes fibrogenic responses in multicellular HLOs through mitochondrial dysfunction and immune-mediated stellate cell activation. These findings support HLOs as a human-relevant platform for investigating AGE-driven hepatic pathology associated with steatosis.